Skip to content

US · LXRX · BIOTECHNOLOGY

Lexicon Pharmaceuticals, Inc. (LXRX) intrinsic value and stock valuation

$1.53as of 2026-11-21 · Mkt cap 1.09B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Lexicon Pharmaceuticals, Inc. DCF and intrinsic value

InvestorsCraft values LXRX with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from LXRX’s statements →

Lexicon Pharmaceuticals, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology The Woodlands, TX 77381 lexpharma.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$49.8M+15.7% 5y CAGRd
20112025
Net income
-$-50.34M
20112025
Free cash flow
-$-67.85M
20112025
Total equity
$107.5M-7.2% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$49.8M$31.1M$1.2M$140K$300K
Operating income-$-48.91M-$-197.12M-$-171.75M-$-100.76M-$-87.09M
Net income-$-50.34M-$-200.4M-$-177.12M-$-101.94M-$-87.76M
EPSd-$-138.66K-$-626.19K-$-800.98K-$-615.1K-$-602.54K
Operating cash flow-$-67.85M-$-178.78M-$-161.9M-$-88.85M-$-87.02M
Capital expenditure$0.00-$-1.03M-$-470K-$-1.33M-$-1.22M
Free cash flow-$-67.85M-$-179.81M-$-162.37M-$-90.18M-$-88.24M
Total assets$185M$298.4M$229.4M$194.3M$136.9M
Total debt$62.2M$108.4M$106.1M$55.3M$2.28M
Net debt$27.9M$41.7M$83.6M$8.95M-$-61.79M
Total equity$107.5M$146M$93.1M$117.1M$113.6M
Cash and short-term investments$96.2M$238M$170M$138.4M$86.7M
Income statement
20252024202320222021
Revenue$49.8M$31.1M$1.2M$140K$300K
Cost of revenue$270K$620K$59M$52.5M$55.1M
Gross profit$49.5M$30.5M-$-57.77M-$-52.38M-$-54.75M
Research and development expenses$61.1M$84.5M$58.9M$52.8M$55.1M
Selling, general and administrative expenses$37.3M$131.9M$0.00$0.00$0.00
Other expenses$0.00$11.2M$55.1M-$-4.43M-$-22.7M
Operating expenses$98.4M$227.6M$114M$48.4M$32.3M
Cost and expenses$98.7M$228.2M$173M$100.9M$87.4M
Interest income$6.91M$12.3M$7.73M$1.6M$130K
Interest expense$8.34M$15.6M$13.1M$2.78M$800K
Depreciation and amortization$620K$530K$550K$430K$290K
Ebitda-$-41.38M-$-184.29M-$-169.76M-$-100.03M-$-86.66M
Operating income-$-48.91M-$-197.12M-$-171.75M-$-100.76M-$-87.09M
Total other income/expenses, net-$-1.43M-$-3.29M-$-5.37M-$-1.18M-$-670K
Income before tax-$-50.34M-$-200.4M-$-177.12M-$-101.94M-$-87.76M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-50.34M-$-200.4M-$-177.12M-$-101.94M-$-87.76M
Weighted average shares outstanding$363.1M$320M$221.1M$165.7M$145.7M
Weighted average diluted shares outstanding$363.1M$320M$221.1M$165.7M$145.7M
Balance sheet
20252024202320222021
Cash and short-term investments$96.2M$238M$170M$138.4M$86.7M
Net receivables$2.38M$3.47M$1.01M$30K$10K
Inventory$280K$230K$380K$0.00$0.00
Total current assets$101.9M$246.2M$176.6M$140.9M$88.9M
Property, plant and equipment, net$9.18M$7.32M$7.51M$8.48M$3.44M
Goodwill and intangible assets$44.5M$44.5M$44.5M$44.5M$44.5M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$83.1M$52.2M$52.9M$53.4M$48M
Total assets$185M$298.4M$229.4M$194.3M$136.9M
Accounts payable$3.08M$14.8M$14.4M$10.4M$9.15M
Short-term debt$6.24M$1.18M$1.29M$1.29M$1.09M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$20.9M$45.3M$31.6M$23.2M$22.1M
Long-term debt$56M$107.2M$104.8M$54M$1.19M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$56.6M$107.2M$104.8M$54M$1.19M
Capital lease obligations$6.59M$8.1M$6.56M$6.71M$2.28M
Total liabilities$77.5M$152.5M$136.3M$77.2M$23.3M
Common stock$370K$360K$240K$190K$150K
Retained earnings-$-2.02B-$-1.97B-$-1.77B-$-1.59B-$-1.49B
Accumulated other comprehensive income (loss)$30K$120K$30K-$-430K-$-10K
Total equity$107.5M$146M$93.1M$117.1M$113.6M
Total investments$61.9M$171.3M$147.6M$92M$22.7M
Total debt$62.2M$108.4M$106.1M$55.3M$2.28M
Net debt$27.9M$41.7M$83.6M$8.95M-$-61.79M
Cash flow statement
20252024202320222021
Net income-$-50.34M-$-200.4M-$-177.12M-$-101.94M-$-87.76M
Depreciation and amortization$620K$530K$550K$430K$290K
Stock-based compensation$12.5M$13.5M$14.3M$11.5M$10.6M
Change in working capital-$-26.89M$14.2M$2.66M$400K-$-10.23M
Accounts receivable$1.09M-$-2.46M-$-980K-$-10K$380K
Inventory-$-50K$150K-$-380K$0.00$0.00
Accounts payable-$-30.22M$14.8M$6.45M$80K-$-14.16M
Net cash provided by operating activities-$-67.85M-$-178.78M-$-161.9M-$-88.85M-$-87.02M
Investments in property, plant and equipment$0.00-$-1.03M-$-470K-$-1.33M-$-1.22M
Acquisitions, net$0.00$0.00$0.00$69.8M-$-3.33M
Net cash used for investing activities$113M-$-15.38M-$-49.94M-$-71.08M$2.11M
Common stock issued$70K$60K$138.8M$94.2M$37.1M
Common stock repurchased$0.00-$-1.73M-$-820K-$-860K-$-2.67M
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-48.5M$238.4M$188M$142.2M$22.7M
Net change in cash-$-3.33M$44.2M-$-23.88M-$-17.72M-$-62.2M
Cash at end of period$63.3M$66.7M$22.5M$46.3M$64.1M
Operating cash flow-$-67.85M-$-178.78M-$-161.9M-$-88.85M-$-87.02M
Capital expenditure$0.00-$-1.03M-$-470K-$-1.33M-$-1.22M
Free cash flow-$-67.85M-$-179.81M-$-162.37M-$-90.18M-$-88.24M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Lexicon Pharmaceuticals, Inc.

        Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.

        CEO
        Michael S. Exton
        Employees
        81
        Beta
        1.05

        Explore

        Frequently asked questions

        What is the intrinsic value of Lexicon Pharmaceuticals, Inc. (LXRX)?

        Lexicon Pharmaceuticals, Inc. (LXRX) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is LXRX undervalued?

        LXRX trades at a price of $1.53 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.